Eliot M. Slovin, PhD

slovin

Associate Professor of Pharmaceutical Sciences

 

Education & Experience:

I received a BS from Northern Illinois University and an MA from Rice University in chemistry. This was followed by chemistry and formulation research positions at the Technion (Israel Institute of Technology) and Teva Pharmaceutical Industries, Ltd. A return to graduate studies culminated in the completion of a MS and PhD in Pharmacy (Pharmaceutics) at the University of Wisconsin – Madison where my research focused on drug delivery in general and to vaginal and GI tissues more specifically. Prior to my current UNTHSC position, I held various positions of increasing responsibility at Alcon Research Ltd. – now a Novartis company, where I was actively involved in the design, research and development of novel ophthalmic drug delivery systems and drug carriers.

Teaching Areas & Interests:

While my research career began as a synthetic organic chemist, my primary research interest is in the field of drug delivery. Drug delivery is important to advance therapeutics. Targeted and controlled drug delivery systems can have major influences upon therapeutic efficacy resulting in major improvement in treatment outcome. Development of novel technologies facilitates the delivery of drugs by controlled release mechanisms or alternative routes of administration to achieve a desired therapeutic effect. My research has focused upon the synthesis of novel drug entities and the research and development of the processes of administering pharmaceutical compounds to achieve desired pharmacodynamics in humans. Specifically, chemical research efforts were directed towards the synthesis of various cholecalciferol (Vitamin D3) metabolites for treatment of bone diseases (e.g., osteoporosis) and the synthesis of various haptens of biological interest attached to metal ions for the development of a novel immunoassay based upon Atomic Absorption. Pharmaceutical research efforts have been the development of the formulation of solid parenteral and various non-parenteral dosage forms for GI and ophthalmic applications. Most recently, major efforts have been towards the design and development of novel drug delivery systems, carriers and formulations to deliver drug to the posterior region of the eye for the treatment of diseases such as macular degeneration and diabetic retinopathy. These efforts have resulted in a number of marketed proprietary and generic formulations. In addition, these research efforts have led to some 12 published papers, an invited book chapter and more than 8 patents and patent applications.

Journals:

In-Vivo Swelling Kinetics of a Series of Hydrogel Polymers in the Cannulated Gastrointestinal Tract of the Canine. Eliot M. Slovin and Joseph R. Robinson, International Journal of Pharmaceutics, 155(1), 53-63 (1997).

Comparative Permeabilities of Some Solutes across the Uterus, Vagina and Vestibule of the Rabbit Doe. Eliot M. Slovin and Joseph R. Robinson, STP Pharma, 6 (6), 430-434 (1996).

Comparative Study in Rabbit Vaginal and Uteral Tissue; E.M. Slovin and J.R. Robinson. Presented at the American Association of Pharmaceutical Scientists Annual Meeting, November 6-10, 1994. Pharmaceutical Research, 11, S-257, (1994).

Use of Malic Acid as a Chiral Synthon: 24,25-Dihydroxycholecalciferol; J. Sterling, E. Slovin, D. Barasch, Tetrahedron Letters, 28, 1685 (1987).

Metalloimmunoassay; M. Cais, S. Dani, Y. Eden, O. Gandolfi, M. Horn, E.E. Isaacs, Y. Josephy, Y. Saar, E. Slovin, L. Snarsky. Nature, 2706, 534, (1977).

Metalloimmunoassay II; M. Cais, E. Slovin, L. Snarsky, Journal of Organometallic Chemistry, 160, 223, (1978).

Books:

Bioadhesives in Ocular Drug Delivery; E.M. Slovin and J.R. Robinson, in Biopharmaceutics of Ocular Drug Delivery, P. Edman, ed., CRC Press, Boca Raton, Fla., 1992.

An efficient, non-photochemical synthetic approach to Vitamin D metabolites and analogues; J. Sterling, D. Barasch, E. Slovin, D. Hirsch, D. Leonov, A. Schwartz, B. Weiner, in Trends in Medicinal Chemistry ‘90, S. Sarel, R. Mechoulam, I. Agranat, eds., Blackwell Scientific Publications, Boca Raton, Fla., 1992.

Intellectual Property:

Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates.
Persyn; Joseph T., McDonough; Joseph A., Vail; Neal K., Barlow; Darren E., Zwiener; Albert M., Slovin; Eliot M.
U.S. Patent 9,693,967. July 4, 2017.

Use of Cyclodextrins as an Active Ingredient for Treating Dry AMD and Solubilizing Drusen. Marsh, David Allen, Collier Jr., Robert J., Kapin, Michael A., Tian, Youqin, Slovin, Eliot Mark.
U. S. Patent 8,158,609. April 17, 2012.

Methods for Preparing Biodegradable Microparticle Formulations Containing Pharmaceutically Active Agents. Persyn, Joseph T.; McDonough, Joseph A.; Vail, Neal K.; Barlow, Darren E.; Zwiener, Albert M.; Slovin, Eliot M.
U.S. Patent 7,758,778. July 20, 2010.

Apparatus for Preparing Biodegradable Microparticle Formulations Containing Pharmaceutically Active Agents. Persyn, Joseph T.; McDonough, Joseph A.; Vail, Neal K.; Barlow, Darren E.; Zwiener, Albert M.; Slovin, Eliot M.
U.S. Patent 7,261,529. August 28, 2007.

Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use. Howie, Janet D., Slovin, Eliot M., Marsh, David A., Kabra, Bhagwati P.
U.S. Patent Application 20070184089. August 9, 2007.

Production of Cholecalciferol derivatives and novel intermediates used therefor; J. Sterling, E. Slovin, D. Barasch, B. Z. Weiner, D. Hirsch.
European Patent EP230600B1. June 27, 1990.

Process for the Stereospecific Preparation of 24(R), 25- and 24(S), 25-dihydroxycholecalciferol and novel intermediates used therefor; J. Sterling, E. Slovin, D. Barasch, B. Z. Weiner, D. Hirsch.
U.S. patent 4,758,382. July 19, 1988.

Production of Cholecalciferol derivatives and novel intermediates used therefor; J. Sterling, E. Slovin, D. Barasch, B. Z. Weiner, D. Hirsch.
Israeli Patent IL1986000077668. January 21, 1986

Link to Dr. Slovin’s University Profile

 

This page was last modified on October 28, 2018